Unaudited Condensed Consolidated Statements of Cash Flows - USD ($)	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Cash flows from operating activities:
Net loss	$ (10,214,365)	$ (12,071,573)
Adjustment to reconcile net loss to net cash used in operating activities:
Stock based compensation	1,235,342	1,577,540
Interest accrued on note receivable	(27,219)	(54,441)
Change in fair value of note receivable	560,473	37,416
Write-off of construction-in-process		747,348
Depreciation and amortization	280,775	246,695
Changes in operating assets and liabilities:
Research and development tax incentive receivable	24,913	(122,269)
Prepaid assets and other current assets	586,432	767,746
Accounts payable	400,293	88,507
Accrued liabilities	872,739	(4,430)
Deferred revenue	(76,000)
Operating lease obligation	(41,130)	(36,453)
Net cash used in operating activities	(6,397,747)	(8,823,914)
Cash flows from investing activities:
Purchases of property and equipment		(35,709)
Net cash used in investing activities		(35,709)
Cash flows from financing activities:
Sales of common stock through ATM	306,086
Payment of offering costs in connection with ATM	(82,729)	(77,149)
Sales of common stock and warrants through offerings, net of offering costs	5,102,519
Net cash provided by (used in) financing activities	5,325,876	(77,149)
Effect of exchange rate changes on cash and cash equivalents	(19,044)	(12,575)
Net change in cash and cash equivalents	(1,090,915)	(8,949,347)
Cash and cash equivalents at beginning of period	5,478,113	16,612,315
Cash and cash equivalents at end of period	4,387,198	7,662,968
Supplemental disclosure of cash flow information:
Cash paid for income taxes
Cash paid for interest	22,988
Supplemental disclosure of non-cash investing and financing activities:
Conversion of note receivable into common stock of Augmenta	1,776,746
Exchange of Augmenta common stock for common stock of Vaxanix	$ 1,776,746